The Center said on Thursday that India is outside the biotech’s country-developed Covaxin clinical trial mode and has now received approval to use it in a restricted emergency. Addressing a weekly press conference, Dr. VK Paul, Member (Health), NITI Aayog, said that covaxin has been approved for restricted use in the event of an emergency in the public interest. And both the COVID-19 vaccine, manufactured by Bharat Biotech’s Kovaxin and Serum Institute, now have the same license status.
Paul said that both the COVID-19 vaccine, Kovaxin and Kovishield have the same status. Covaxine has been proven to be a good safety. Only 311 individuals had very few side effects. It is a victory of India’s research and development enterprise and science and technology enterprise.
India’s drug regulator had on January 3 approved the restricted use of covaxin in emergency situations in the public interest. This was done as a major precaution in the clinical trial mode, especially in the case of infection with mutant strains.
Second phase of vaccination released from March 1
The second dose of COVID-19 vaccine was started from 13 February, which has completed 28 days after getting the first dose. Vaccination of Frontline Workers (FLWs) began on 2 March. The second phase of the COVID-19 vaccination commenced from March 1, in which people over the age of 60 and those above 45 who have a reported co-morbid condition will be given a dose. .
The company had said in January that the company would pay compensation in the event of any serious side effects after taking its vaccine. The company has received an order from the government to purchase supplies of 55 lakh doses. In the Consent form signed by the people taking the vaccine, Bharat Biotech said that in the event of a bad event or a serious bad event, you will be provided with standard care in government-designated and certified centers or hospitals.